Clinical Trials Logo

Neonatal Abstinence Syndrome clinical trials

View clinical trials related to Neonatal Abstinence Syndrome.

Filter by:

NCT ID: NCT01175668 Terminated - Clinical trials for Neonatal Abstinence Syndrome

Clonidine for Neonatal Abstinence Syndrome Study

Start date: July 2010
Phase: N/A
Study type: Interventional

The study plans to compare the use of Clonidine versus Phenobarbital as an additional medication to neonatal morphine sulfate for treatment of newborn infants undergoing drug withdrawal symptoms due to mother's use of opioid drug use. The investigators hypothesis is that use of Clonidine will lead to shorter duration of treatment, hospital stay and thereby early discharge home.

NCT ID: NCT00521248 Completed - Clinical trials for Neonatal Abstinence Syndrome

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Start date: April 2004
Phase: Phase 1
Study type: Interventional

Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with buprenorphine is associated shorter stays in the hospital and fewer days of treatment than the use of standard therapy. Another secondary goal will be to understand buprenorphine concentration in the blood of babies treated with the drug (this is called "pharmacokinetics").

NCT ID: NCT00510016 Completed - Clinical trials for Neonatal Abstinence Syndrome

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

NAS
Start date: July 2002
Phase: Phase 2
Study type: Interventional

To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.

NCT ID: NCT00496951 Completed - Clinical trials for Neonatal Abstinence Syndrome

Vagal Tone and Neonatal Abstinence Syndrome

NAS
Start date: September 2006
Phase: N/A
Study type: Observational

Symptoms of Neonatal Abstinence Syndrome (NAS) can be attributed largely to dysfunction of the autonomic nervous system in opiate exposed neonates. Vagal tone is a readily available measure of autonomic nervous system functioning. NAS is a widely variable disorder with poorly understood pathophysiology; while all opiate exposed infants will exhibit some signs and symptoms of NAS, only approximately ½ have severe enough symptoms to require pharmacologic therapy. This research seeks to determine the relationship between infant vagal tone and NAS severity. The determination of a link between newborn vagal tone and NAS severity could result in the prediction of infants at risk for severe NAS and provide these infants and mothers with intensified services and early treatment, thereby shortening the course of NAS in the infant.

NCT ID: NCT00225316 Completed - Substance Addiction Clinical Trials

Maternal Acupuncture for Substance Abuse

Start date: August 2005
Phase: Phase 3
Study type: Interventional

To determine the efficacy of daily maternal acupuncture treatments in reducing the frequency and severity of neonatal abstinence syndrome among infants born to substance-using women..

NCT ID: NCT00218621 Completed - Pregnancy Clinical Trials

The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1

Start date: September 2005
Phase: Phase 2
Study type: Observational

The purpose of this study is to evaluate the effects of drugs used by treatment providers on the fetuses and infants of opiate dependent women. The subjects in this study are women enrolled in a large, multi-site, double blind study that looks at the effects of methadone and buprenorphine treatment during pregnancy. This study will evaluate fetal and maternal biophysiologic data longitudinally during pregnancy to determine how these substances may affect fetal neurobehavior. Additionally, infant neurobehavioral assessments and measurements of infant vagal tone will be collected to see how methadone and buprenorphine differentially affect the neonatal abstinence syndrome, or "withdrawal" in exposed neonates.